REGENERON PHARMACEUTICALS, INC.
TARRYTOWN, NY · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 5, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$179.6M2026 Q3
Positions3
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.100.0%
REGENERON PHARMACEUTICALS, INC. reported 3 positions worth $179.6M as of September 30, 2026 (13F filed November 5, 2026). Largest holding: PBLS (74.9%).
3 positions shown
Read the 2026-Q2 quarterly report · 13F Filing Calendar
Frequently Asked Questions
What stocks does REGENERON PHARMACEUTICALS, INC. hold as of Q3 2026?
REGENERON PHARMACEUTICALS, INC. reported 3 positions worth $179.6M in its Q3 2026 13F filing. Largest positions: PBLS (74.9%), NTLA (24.9%) and ACET (0.2%).
What did REGENERON PHARMACEUTICALS, INC. buy in Q3 2026?
REGENERON PHARMACEUTICALS, INC. opened or added to no positions in Q3 2026.
What did REGENERON PHARMACEUTICALS, INC. sell in Q3 2026?
REGENERON PHARMACEUTICALS, INC. reduced or sold out of no positions in Q3 2026.
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.